https://retacompare.com/news/insights-on-glp-1-agonists-for-optimal-obesity-treatment-outcomes 2026-10-23T18:00:00.000Z RetatrutideCompare en 2026-10-23T18:00:00.000Z Insights on GLP-1 Agonists for Optimal Obesity Treatment Outcomes Weight Loss, Retatrutide https://retacompare.com/news/retatrutide-s-role-in-weight-loss-explored-in-recent-report 2026-10-23T16:59:10.000Z RetatrutideCompare en 2026-10-23T16:59:10.000Z Retatrutide's Role in Weight Loss Explored in Recent Report Weight Loss, Retatrutide https://retacompare.com/news/glp-1-market-growth-in-emerging-economies-may-hit-22-billion-by-2035 2026-10-23T10:02:25.000Z RetatrutideCompare en 2026-10-23T10:02:25.000Z GLP-1 Market Growth in Emerging Economies May Hit $22 Billion by 2035 Market News, Retatrutide https://retacompare.com/news/retatrutide-reduces-sleep-apnea-severity-in-type-2-diabetes-patients 2026-10-23T09:15:39.000Z RetatrutideCompare en 2026-10-23T09:15:39.000Z Retatrutide Reduces Sleep Apnea Severity in Type 2 Diabetes Patients Clinical Trials, Retatrutide https://retacompare.com/news/korea-to-launch-first-glp-1-obesity-drug-eppe-on-october-29 2026-10-23T03:31:23.000Z RetatrutideCompare en 2026-10-23T03:31:23.000Z Korea to Launch First GLP-1 Obesity Drug Eppe on October 29 Market News, Retatrutide https://retacompare.com/news/glp-1-agonists-show-weight-loss-and-blood-pressure-benefits-in-obesity 2026-10-23T01:27:05.597Z RetatrutideCompare en 2026-10-23T01:27:05.597Z GLP-1 Agonists Show Weight Loss and Blood Pressure Benefits in Obesity Clinical Trials, Retatrutide https://retacompare.com/news/retatrutide-s-potential-fda-approval-timeline-for-2026-discussed 2026-10-23T00:27:30.000Z RetatrutideCompare en 2026-10-23T00:27:30.000Z Retatrutide's Potential FDA Approval Timeline for 2026 Discussed Market News, Retatrutide https://retacompare.com/news/glp-1-therapies-in-cardiovascular-care-new-clinical-insights 2026-10-23T00:00:00.000Z RetatrutideCompare en 2026-10-23T00:00:00.000Z GLP-1 Therapies in Cardiovascular Care: New Clinical Insights Clinical Trials, Retatrutide https://retacompare.com/news/advancements-in-incretin-based-therapeutics-explored 2026-10-23T00:00:00.000Z RetatrutideCompare en 2026-10-23T00:00:00.000Z Advancements in Incretin-Based Therapeutics Explored Clinical Trials, Retatrutide https://retacompare.com/news/gut-liver-axis-in-pediatric-liver-disease-implications-for-glp-1-research 2026-10-23T00:00:00.000Z RetatrutideCompare en 2026-10-23T00:00:00.000Z Gut-Liver Axis in Pediatric Liver Disease: Implications for GLP-1 Research Clinical Trials, Retatrutide https://retacompare.com/news/fda-approval-anticipated-for-weight-loss-drugs-by-2026 2026-10-22T23:04:37.000Z RetatrutideCompare en 2026-10-22T23:04:37.000Z FDA Approval Anticipated for Weight Loss Drugs by 2026 Market News, Retatrutide https://retacompare.com/news/fda-raises-concerns-over-unapproved-glp-1-drugs-including-retatrutide 2026-10-22T23:03:30.000Z RetatrutideCompare en 2026-10-22T23:03:30.000Z FDA Raises Concerns Over Unapproved GLP-1 Drugs Including Retatrutide Market News, Retatrutide https://retacompare.com/news/glp-1-drugs-show-potential-in-treating-skin-conditions 2026-10-22T22:32:21.000Z RetatrutideCompare en 2026-10-22T22:32:21.000Z GLP-1 Drugs Show Potential in Treating Skin Conditions Clinical Trials, Retatrutide https://retacompare.com/news/retatrutide-reduces-kidney-stress-markers-in-obesity-and-ckd 2026-10-22T21:05:10.000Z RetatrutideCompare en 2026-10-22T21:05:10.000Z Retatrutide Reduces Kidney Stress Markers in Obesity and CKD Clinical Trials, Retatrutide https://retacompare.com/news/exploring-the-peptide-economy-beyond-glp-1-advancements 2026-10-22T20:58:29.000Z RetatrutideCompare en 2026-10-22T20:58:29.000Z Exploring the Peptide Economy Beyond GLP-1 Advancements Market News, Retatrutide